Literature DB >> 10199329

Brain tumors in children.

R J Packer1.   

Abstract

Childhood brain tumors are the leading cause of cancer-related morbidity and mortality in the pediatric years and differ from primary central nervous system tumors occurring in adults. Management strategies must take into account not only the tumor type, but the age of the patient and the likelihood of treatment-induced nervous system damage. With current means of treatment, most children older than 3 years can be effectively treated. Chemotherapy has taken on an increasing role in the treatment of childhood medulloblastomas, low-grade gliomas, and high-grade gliomas. Some tumor types, especially atypical teratoid tumors, brainstem gliomas, malignant gliomas, and malignant infantile tumors, remain significant therapeutic dilemmas.

Entities:  

Mesh:

Year:  1999        PMID: 10199329     DOI: 10.1001/archneur.56.4.421

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  28 in total

Review 1.  Gene expression profiling to analyze embryonal tumors of the central nervous system.

Authors:  Roger J Packer
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

2.  Dmp53 protects the Drosophila retina during a developmentally regulated DNA damage response.

Authors:  Omar W Jassim; Jill L Fink; Ross L Cagan
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

3.  ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration.

Authors:  Liangping Yuan; Mariarita Santi; Elisabeth J Rushing; Robert Cornelison; Tobey J MacDonald
Journal:  Clin Exp Metastasis       Date:  2010-06-06       Impact factor: 5.150

4.  Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma.

Authors:  Adam W Studebaker; Brian Hutzen; Christopher R Pierson; Stephen J Russell; Evanthia Galanis; Corey Raffel
Journal:  Neuro Oncol       Date:  2012-02-03       Impact factor: 12.300

5.  Balance control in sitting and standing in children and young adults with benign cerebellar tumors.

Authors:  Beate Schoch; Aidan Hogan; Elke R Gizewski; Dagmar Timmann; Juergen Konczak
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

6.  Effect of Nigella sativa seed administration on prevention of febrile neutropenia during chemotherapy among children with brain tumors.

Authors:  HebatAlla Fathi Mohamed Mousa; Nesrin Kamal Abd-El-Fatah; Olfat Abdel-Hamid Darwish; Shehata Farag Shehata; Shady Hassan Fadel
Journal:  Childs Nerv Syst       Date:  2017-03-27       Impact factor: 1.475

7.  An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Authors:  Fadila Guessous; Ying Zhang; Charles diPierro; Lukasz Marcinkiewicz; Jann Sarkaria; David Schiff; Sean Buchanan; Roger Abounader
Journal:  Anticancer Agents Med Chem       Date:  2010-01       Impact factor: 2.505

8.  Feasibility of long-term intraventricular therapy with mafosfamide (n = 26) and etoposide (n = 11): experience in 26 children with disseminated malignant brain tumors.

Authors:  Irene Slavc; Elisabeth Schuller; Jutta Falger; Mehmet Günes; Konrad Pillwein; Thomas Czech; Wolfgang Dietrich; Karl Rössler; Karin Dieckmann; Daniela Prayer; Johannes Hainfellner
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

9.  Substantiating in vivo magnetic brain tumor targeting of cationic iron oxide nanocarriers via adsorptive surface masking.

Authors:  Beata Chertok; Allan E David; Bradford A Moffat; Victor C Yang
Journal:  Biomaterials       Date:  2009-09-25       Impact factor: 12.479

10.  Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis.

Authors:  Judith M de Bont; Johan M Kros; Monique M C J Passier; Roel E Reddingius; Peter A E Sillevis Smitt; Theo M Luider; Monique L den Boer; Rob Pieters
Journal:  Neuro Oncol       Date:  2008-06-24       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.